Transfer of Autologous T Cells Transduced With the Anti-MART-1 F5 T Cell Receptor in High Risk Melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melanoma vaccine (Primary) ; Melanoma vaccine (Primary) ; Aldesleukin; Incomplete Freund's adjuvant
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 28 Oct 2015 Biomarkers information updated
- 18 Mar 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.